Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/9/2025 | $280.00 → $255.00 | Outperform | Telsey Advisory Group |
| 4/3/2025 | $410.00 → $130.00 | Buy → Underperform | BofA Securities |
| 4/3/2025 | $200.00 | Buy → Neutral | Citigroup |
| 4/3/2025 | $420.00 → $280.00 | Outperform | Telsey Advisory Group |
| 3/24/2025 | $500.00 → $420.00 | Outperform | Telsey Advisory Group |
| 1/30/2025 | $261.00 → $374.00 | Sell → Neutral | Goldman |
| 1/13/2025 | $435.00 → $530.00 | Equal-Weight → Overweight | Morgan Stanley |
| 1/8/2025 | $383.00 → $515.00 | Equal Weight → Overweight | Barclays |
Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:
Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:
Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/15/2021. Application Category: ANDA, Application Number: 213111, Application Classification: